Format

Send to

Choose Destination
J Clin Invest. 2007 May;117(5):1184-94.

Development of TLR9 agonists for cancer therapy.

Author information

1
Coley Pharmaceutical Group, 93 Worcester Street, Wellesley, MA 02481, USA. akrieg@coleypharma.com

Abstract

In vertebrates, the TLRs are a family of specialized immune receptors that induce protective immune responses when they detect highly conserved pathogen-expressed molecules. Synthetic agonists for several TLRs, including TLR3, TLR4, TLR7, TLR8, and TLR9, have been or are being developed for the treatment of cancer. TLR9 detects the unmethylated CpG dinucleotides prevalent in bacterial and viral DNA but not in vertebrate genomes. As discussed in this Review, short synthetic oligodeoxynucleotides containing these immune stimulatory CpG motifs activate TLR9 in vitro and in vivo, inducing innate and adaptive immunity, and are currently being tested in multiple phase II and phase III human clinical trials as adjuvants to cancer vaccines and in combination with conventional chemotherapy and other therapies.

PMID:
17476348
PMCID:
PMC1857270
DOI:
10.1172/JCI31414
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center